Remote Ischemic Preconditioning in Septic Patients
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversität Münster
About this trial
Acute kidney injury is a well-recognized complication in critically ill patients. Up to date there is no clinically established method to reduce the incidence or the severity of acute kidney injury.
Remote ischemic preconditioning (RIPC) will be induced by three cycles of upper limb ischemia.
The aim of the study is to reduce the incidence of AKI by implementing remote ischemic preconditioning (identified by the urinary biomarkers tissue inhibitor of metalloproteinases-2 (TIMP-2) and insulin-like growth factor-binding protein 7(IGFBP7)
Eligibility criteria
Qualifiers
Adult patients (age ≥18 years)
Critically ill patients with sepsis < 12 hours
Invasive ventilation for at least 24 hours (propofol-free-sedation) and/or vasopressor therapy
Unrestricted intensive care for at least 72 hours
Disqualifiers
Pre-existing AKI
(Glomerulo-)nephritis, interstitial nephritis, vasculitis
Chronic kidney disease with estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73m²
Chronic dialysis dependency
Trial design
Treatments tested in this trial
- Remote ischemic preconditioning (RIPC)
- Sham RIPC
Treatment groups
64 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov